ABCL-509 Healthcare Utilization and Costs in Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma

Nathan Denlinger,Ying Huang,Zachary Braunstein,Audrey Sigmund,Amneet Bajwa,Nilesh Kapoor,Akwasi Agyeman, Scott Fisher, Zebulun Purdin,Alison Neal,Filiz Yucebay,Julianna Roddy,Jonathan Brammer,Basem William,Ayman Saad,Sam Penza,Timothy Voorhees,Adam Kittai,Marcos de Lima,Sumithira Vasu

Clinical Lymphoma Myeloma and Leukemia（2022）

引用 0|浏览9

暂无评分

摘要

We observed higher hospital charges, LOS, and toxicity with axi-cel compared to tisa-cel. Patients with Medicare more frequently incurred out of pocket costs and hospital losses were driven by inpatient infusions for patients with Medicare. More robust retrospective studies are needed to further investigate our findings.

查看译文

关键词

ABCL,CAR T,lymphoma,cost,toxicity,insurance

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要